A pioneering research achievement by CSPC Pharmaceutical Group has been published in the internationally renowned authoritative journal Science Advances.

2026-03-17 12:17:07

People’s Financial News, March 17 — According to CSPC Pharmaceutical Group, recently, a research study on gene editing therapy for transthyretin amyloidosis (ATTR), conducted collaboratively by Dr. Li Chunlei and Dr. Su Xiaoye from CSPC Pharmaceutical Group, along with Professor Gan Jianhua from Fudan University as co-corresponding authors and Dr. Qi Sixian as the first author, was published in the internationally renowned journal Science Advances. The study systematically explores the application of high-fidelity SpCas9 mutants in the treatment of ATTR, providing important evidence to promote the clinical translation of related therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.